Hydroxychloroquine pre-exposure prophylaxis provides no protection against COVID-19 among health care workers: a cross-sectional study in a tertiary care hospital in North India

J Basic Clin Physiol Pharmacol. 2022 Jan 7;33(1):103-107. doi: 10.1515/jbcpp-2021-0221.

Abstract

Objectives: The use of Hydroxychloroquine (HCQ) prophylaxis has been recommended by the National task force constituted by the Indian Council of Medical Research (ICMR) for the prevention of corona virus disease 2019 (COVID-19) among healthcare workers (HCWs). However, this recommendation was based essentially on the preclinical data and limited clinical experience. The aim of this study was to evaluate the efficacy and safety of HCQ as a pre-exposure prophylaxis for COVID-19 infection among Indian HCWs.

Methods: A cross-sectional study was conducted among HCWs of a tertiary care hospital in north India. The HCQ prophylaxis was initiated among 996 HCWs and they were followed up to 8 weeks for conversion to COVID-19 positive status and any adverse drug reaction (ADR).

Results: About 10.3% of the study participants were tested positive for COVID-19 which was comparable to the positivity rate among HCWs not taking HCQ prophylaxis (9.7%).

Conclusions: HCQ was well tolerated at a weekly dose of 400 mg for 8 weeks but provided no additional benefit in prevention of COVID-19 among HCWs.

Keywords: COVID-19; Hydroxycholoroquine; prophylaxis.

MeSH terms

  • COVID-19 Drug Treatment*
  • COVID-19* / prevention & control
  • Cross-Sectional Studies
  • Health Personnel
  • Humans
  • Hydroxychloroquine / administration & dosage*
  • India
  • Pre-Exposure Prophylaxis*
  • Tertiary Care Centers
  • Treatment Failure

Substances

  • Hydroxychloroquine